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 Breast cancer is the most common form of cancer in
American women and is the leading cause of death
between the ages of 40-44 years old.
 1 in 8 women will develop breast cancer in their lifetime,
an alarming statistic and one that is becoming more
prevalent in our country.
 The purpose of this research paper was to investigate
prophylactic medication use for women who are at high
risk for developing breast cancer, specifically evaluating
whether the common diabetic medication Metformin is an
effective prophylactic medication in these individuals
prior to the onset of any type of cancer.

Abstract
 Breast cancer is one of the most common types of
cancer in American women and is the second leading
cause of mortality.
 In 2015, 234,190 new diagnoses were made and 40,730
deaths from breast cancer.
 Along with a thorough history from the patient, there
are also several risk assessment models that should be
utilized, such as the common Gail-2 model.
 Any women with a significant family history should
also be educated on genetic counseling and/or testing to
detect a BRCA1 or 2 mutation.
 Numerous individuals who are positive for this gene
elect to undergo prophylactic treatment, such as an
oophorectomy, mastectomy or the use of Tamoxifen, or
an aromatase inhibitor, also called selective estrogen
receptor modulators or SERMS.
 These medications reduce the amount of estrogen in the
body, have been shown to reduce cases of breast cancer,
but also come with side effects, such as an increased
risk of endometrial cancer, cataracts or venous
thrombolytic events.

Research Questions
 Will the prophylactic use of metformin in high-risk women,
decrease their overall risk of developing breast cancer?
 Is the use of prophylactic metformin in high-risk women
safe and effective in preventing certain types of breast
cancer?

Statement of the Problem
 With the number of women diagnosed annually with a new
onset of breast cancer, it is important to determine their
overall risk factor for this development prior to their
diagnosis. The current research suggests that the only way to
prevent breast cancer is by early detection with annual
mammogram screening.
 There is conflicting evidence out there to suggest current
self-breast exams, as well as clinician performed breast
exams for the detection of breast cancer, as it currently does
not improve survival rates. Also, mammography is the most
“reliable means of detecting breast cancer before a mass can
be palpated, and most slowly growing cancers can be
identified by mammography at least 2 years before reaching
a size detectable by palpation.”(Papadakis, et al, 2017).

Factors associated with increased risk of breast cancer
Race

Caucasian

Age

Older; Typically, post-menopausal

Family history

Breast cancer in parent, sibling, or child. (higher risk if bilateral
or premenopausal).
BRACA1 or BRACA2 mutation

Genetics
Previous medical history
Menstrual history
Reproductive history

Endometrial cancer, Proliferative forms of fibrocystic disease,
cancer of the other breast.
Early menarche (<12 years old)
Late Menopause (>50 years old)
Nulliparous or late first pregnancy (>30 years old)

Table 1: Current Diagnosis and Treatment.(Papadakis; McPhee, 2017)

Literature Review
 Insulin growth factors or IGFs are involved in malignancy and cell
proliferation, as well as apoptosis. This IGF is a protein hormone that when
stimulated by insulin, promotes synthesis and biologic activity.
 McCance (2014) states that, “Insulin also can promote the synthesis and
biologic availability of the male and female sex hormones, including
estrogens, progesterone and androgens.” Proliferation of breast cancer, as
well as normal epithelial cells can occur due to this IGF. High levels of
fasting insulin were found to be associated with a two to threefold increase
in the risk of mortality from cancer.
 Studies show an association between IGF-1 and breast cancer, not affected
by menopausal state.
 Pollak (2000) found that IGF’s are associated with the regulation of cell
proliferation and positively related to common cancers, specifically
premenopausal breast cancer. Research has shown that individuals who have
higher levels of IGF’s are at a higher predisposition of developing cancer
compared to individuals who have low to normal levels of IGF’s.
 (Ko, 2014): Looking at endometrial cancer, individuals in this study who
were non-metformin users had worse recurrence free survival rates (95% Cl;
p=0.02) and worsened overall survival by 2.3 times (95% Cl; p=0.005).
 (Libby, et al., 2014): Researched new users of metformin in type II diabetics.
They concluded that metformin users are at a lower risk overall of
developing cancer compared to diabetics on other medications. (95% Cl;
0.46 hazard ratio). They also concluded that once diagnosed with cancer,
users of metformin had a decreased mortality rate of 14.9% compared to
non-users mortality rate of 34.8%.
 (Tsilidis et al., 2014): Challenged Libby’s study by concluding that
metformin does not affect cancer risk. They compared two diabetic
medications, with similar incidence of postmenopausal breast cancer (95%
Cl; HR 1.03). However, this trial wanted to improve their hazard ratios and
at the end of the study they adjusted this by excluding smoking status, BMI,
alcohol consumption, use of aspirin or NSAIDS, statins, diabetes duration
and the year the first prescription was ordered of the diabetic medication,
which narrowed this down to a selected population and perhaps skewed the
results.
 (Bodmer, 2010): Acknowledged that type II diabetes was associated with
increased epithelial proliferation and certain types of cancer due to
hyperinsulinemia and insulin resistance. It was concluded that short term
users of metformin had no change in odds ratio, but comparing >30
prescriptions, or long term use the OR adjusted to 0.63 and furthermore
when they looked at >40 prescriptions, the OR adjusted further to 0.44,
which concluded that long term metformin use was associated with a
decrease incidence in breast cancer.
 (Campagnoli, 2013): Concluded treatment with metformin has a significant
decrease in free testosterone by 29% and estradiol by 38%, thus overall
decreasing the risk of breast cancer, specifically ER-positive breast cancer.
 (Niraula, 2012): Study published investigating newly diagnosed, untreated
women in early stages of operable invasive breast cancer. They also
evaluated pathology reports from tumor biopsies and based these results on
the Ki67 stain numbers which shows how quickly the tumor is proliferating,
as well as the TUNEL methods to determine apoptosis. Results showed Ki67
numbers or proliferation of cells decreased from 36.5 to 33.5 and the
TUNEL method numbers increased from 0.56 to 1.05. With this study, it
was found that metformin has the potential to change the proliferation of
cancer cells, based off the Ki67 and TUNEL methods.
 (Hirsh, 2010): Found metformin may inhibit cell transformation, as well as
inhibiting invasive growth and killing cancer stem cells.
 (Kim, 2014): A current in process trial that is using metformin in conjunction
with Letrozole, a hormone based chemotherapy drug. The goal is to provide
evidence that metformin has direct anti-tumor effects in non-diabetic ER
positive breast cancer women.

Discussion
 The use of metformin, specifically when women are already diagnosed with breast
cancer, shows it’s associated with decreased levels of insulin, specifically in nondiabetic women. The risk of breast cancer increases in obesity, as well as increased
insulin levels and these studies show there is potential to decrease this risk by interacting
with the amount of insulin in the body.
 Increased insulin like growth factors contribute to the development of certain forms of
cancer. Epithelial cells, as well as breast cancer cells proliferate under increased insulin
like growth factors and these growth factors were specifically associated with increased
premenopausal breast cancers.
 After review, it was concluded that increased levels of insulin, testosterone, as well as
estrogen increase breast cancer risk, specifically estrogen receptor or ER positive breast
cancer, as well as recurrence rates and mortality.
 Overall, in the studies found, there were none regarding prophylactic use of metformin
or early use prior to the onset of breast cancer specifically for high risk patients.
However, studies are currently in process, as well as current evidence that suggest
patients who use metformin with type 2 diabetes have an overall decreased risk of
developing any type of cancer.

Applicability to Clinical Practice
 As the research suggested, breast cancer is the leading cause of death between ages 4044 years old, yet there is conflicting recommendations on when to screen low risk
women. Currently, it is recommended to discuss it with women between these ages,
and routine screening with yearly mammograms is recommended at age 45. If there is
a high-risk factor, these recommendations change.
 Currently, the only tool we have to prevent breast cancer is by early detection or in
high risk women a prophylactic double mastectomy, which a lot of women are now
currently undergoing with a positive a BRACA gene.
 If we could begin a medication for these high risk women prior to them having to
undergo a double mastectomy to decrease their overall risk, this is clinically relevant
and may prevent the complications and detrimental changes women undergo after
surgical intervention.
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